Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Vlado Perkovic; Katherine R. Tuttle; Peter Rossing; Kenneth W. Mahaffey; Johannes F.E. Mann; George L. Bakris; Florian M.M. Baeres; Thomas Idorn; Heidrun Bosch‐Traberg; Nanna L. Lausvig; Richard Pratley

doi:10.1056/nejmoa2403347

Abstract

Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo Nordisk; FLOW ClinicalTrials.gov number, NCT03819153.).

Keywords

SemaglutideType 2 diabetesKidney diseaseMedicineDiabetes mellitusInternal medicineEndocrinology

Affiliated Institutions

Related Publications

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding , Rachel L. Batterham , Salvatore Calanna +11 more

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body we...

2021 New England Journal of Medicine 3574 citations

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso , Gilbert H. Daniels , Kirstine Brown‐Frandsen +12 more

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type ...

2016 New England Journal of Medicine 6755 citations

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff , Kirstine Brown‐Frandsen , Helen M. Colhoun +13 more

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo i...

2023 New England Journal of Medicine 1860 citations

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome , Kristine Buchholtz , Kenneth Cusi +6 more

This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placeb...

2020 New England Journal of Medicine 1648 citations

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Mikhail Kosiborod , Steen Z. Abildstrøm , Barry A. Borlaug +28 more

In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, g...

2023 New England Journal of Medicine 1090 citations

Publication Info

Year: 2024
Type: article
Volume: 391
Issue: 2
Pages: 109-121
Citations: 1020
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1020

OpenAlex

Cite This

APA Style

                            
                                
                                    Vlado Perkovic, 
                                
                                    Katherine R. Tuttle, 
                                
                                    Peter Rossing
                                
                                et al.
                            
                            (2024). 
                            Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 391
                            (2)
                            , 109-121.
                            https://doi.org/10.1056/nejmoa2403347
                        

Identifiers

DOI: 10.1056/nejmoa2403347